+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme



PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme



Journal of the National Cancer Institute 93(16): 1246-1256



Background: Survival of patients with anaplastic astrocytoma is highly variable. Prognostic markers would thus be useful to identify clinical subsets of such patients. Because specific genetic alterations have been associated with glioblastoma, we investigated whether similar genetic alterations could be detected in patients with anaplastic astrocytoma and used to identify those with particularly aggressive disease. Methods: Tissue specimens were collected from 174 patients enrolled in Mayo Clinic Cancer Center and North Central Cancer Treatment Group clinical trials for newly diagnosed gliomas, including 63 with anaplastic astrocytoma and 111 with glioblastoma multiforme. Alterations of the EGFR, PTEN, and p53 genes and of chromosomes 7 and 10 were examined by fluorescence in situ hybridization, semi-quantitative polymerase chain reaction, and DNA sequencing. All statistical tests were two-sided. Results: Mutation of PTEN, amplification of EGFR, and loss of the q arm of chromosome 10 were statistically significantly less common in anaplastic astrocytoma than in glioblastoma multiforme (P=.033, P=.001, and P<.001, respectively), and mutation of p53 was statistically significantly more common (P<.001). Univariate survival analyses of patients with anaplastic astrocytoma identified PTEN (P=.002) and p53 (P=.012) mutations as statistically significantly associated with reduced and prolonged survival, respectively. Multivariate Cox analysis of patients with anaplastic astrocytoma showed that PTEN mutation remained a powerful prognostic factor after adjusting for patient age, on-study performance score, and extent of tumor resection (hazard ratio=4.34; 95% confidence interval=1.82 to 10.34). Multivariate classification and regression-tree analysis of all 174 patients identified EGFR amplification as an independent predictor of prolonged survival in patients with glioblastoma multiforme who were older than 60 years of age. Conclusion: PTEN mutation and EGFR amplification are important prognostic factors in patients with anaplastic astrocytoma and in older patients with glioblastoma multiforme, respectively.

(PDF emailed within 0-6 h: $19.90)

Accession: 011112165

Download citation: RISBibTeXText

PMID: 11504770

DOI: 10.1093/jnci/93.16.1246


Related references

Correlation of molecular genetic analysis of p53, MDM2, p16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma. Frontiers in Bioscience 8: E281-E288, 2003

Correlation of molecular genetic analysis of P53 Mdm2 P16 Pten and Egfr and survival of patients with anaplastic astrocytoma and glioblastoma. Frontiers in Bioscience 8(5): e281-288, 2003

Survival of patients with astrocytoma anaplastic astrocytoma and glioblastoma multiforme a review of 90 cases in 3 eortc trials and 90 tumors in a ki67 study. British Journal of Neurosurgery 3(6): 729, 1989

Next generation sequencing and molecular imaging identify EGFR mutation and amplification in a glioblastoma multiforme patient treated with an EGFR inhibitor: a case report. Oncotarget 8(30): 50305-50313, 2017

The conditional probabilities of survival in patients with anaplastic astrocytoma or glioblastoma multiforme. Surgical Neurology 60(5): 402-6; Discussion 406, 2003

Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients. Oncology Reports 15(6): 1513-1516, 2006

Dendritic cell immunotherapy for patients with glioblastoma multiforme and anaplastic astrocytoma. Proceedings of the American Association for Cancer Research Annual Meeting 42: 274-275, 2001

Cerebrospinal fluid polyamines in patients with Glioblastoma multiforme and anaplastic astrocytoma. Cancer Research 40(9): 3293-3296, 1980

A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme. International Journal of Clinical Oncology 8(5): 301-304, 2003

The infrequent simultaneous genetic alterations in glioblastoma multiforme (LOH 10, 17,19q, TP53 mutation and EGFR amplification) with short clinical course. Polish Journal of Pathology 58(2): 79-85, 2007

Phase II clinical trial of didemnin B in patients with recurrent or refractory anaplastic astrocytoma or Glioblastoma multiforme (NSC 325319). Investigational New Drugs 17(2): 179-182, 1999

A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma. Journal of Neuro-Oncology 71(3): 301-305, 2005

Phase I/II trial of superselective arterial 5-FU infusion with concomitant external beam radiation for patients with either anaplastic astrocytoma or glioblastoma multiforme. American Journal of Clinical Oncology 14(6): 514-518, 1991

Genome-wide oligonucleotide microarray analysis of gene-expression profiles of Taiwanese patients with anaplastic astrocytoma and glioblastoma multiforme. Journal of Biomolecular Screening 13(9): 912-921, 2008

Differential expression of HIF-1 in glioblastoma multiforme and anaplastic astrocytoma. International Journal of Oncology 41(4): 1260-1270, 2014